

Rare... but important diseases

Poster Session 67

Monday, 27 March  
12:15 - 13:45

**Location:** Room Stockholm, North Hall (Level 1)

**Chairs:** K. Ghani, Ann Arbor (US)  
G. Pourmand, Tehran (IR)  
K. Thomas, London (GB)

**Aims and objectives of this session**

This session examines a variety of rare and difficult urological diseases.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (\*) are 3 minutes in length, followed by 3 minutes for discussion.

- \*882      **Shorter telomere length increases age-related risk of kidney cancer in von Hippel-Lindau disease**  
**By:** [Wang J.Y.](#), Peng S.H., Ning X.H., Li T., Liu J.Y., Liu S.J., Gong K.  
**Institutes:** Peking University, Institute of Urology, Dept. of Urology, Beijing, China
- 883      **Integrated analysis of microRNA and mRNA expression profiles in tuberous sclerosis complex angiomyolipoma**  
**By:** [Yi C.](#), Li H., Zhang Y.  
**Institutes:** Peking Union Medical College Hospital, Dept. of Urology, Beijing, China
- 884      **Nephron-sparing surgery for renal angiomyolipomas with high nephrometry scores**  
**By:** [Huang T.H.](#), Chang Y-H., Chung H-J., Lin A.T-L.  
**Institutes:** Taipei Veterans General Hospital, Dept. of Urology, Taipei City, Taiwan
- \*885      **Understanding a new clinical entity - a prospective study of patients with immunoglobulin G4-related retroperitoneal fibrosis (IgG4-RPF) in a specialist RPF service**  
**By:** [Fernando A.](#)<sup>1</sup>, Pattison J.<sup>2</sup>, D'Cruz D.<sup>3</sup>, O'Brien T.<sup>1</sup>  
**Institutes:** <sup>1</sup>Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, <sup>2</sup>Guy's and St Thomas' NHS Foundation Trust, Dept. of Nephrology, London, United Kingdom, <sup>3</sup>Guy's and St Thomas' NHS Foundation Trust, Dept. of Immunology, London, United Kingdom
- 886      **Clinicopathologic features and survival outcomes of primary renal sarcoma: A 20-year experience and the largest cohort study from Taiwan**  
**By:** [Liao C-C.](#), Tai H-C., Chen C-H., Wang S-M., Huang C-Y., Pu Y-S., Huang K-H.  
**Institutes:** National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan
- 887      **Male urinary status, fertility and sexuality in complex extrophy epispadias: A descriptive study**  
**By:** [Reynaud N.](#)<sup>1</sup>, Charvier K.<sup>2</sup>, Ruffion A.<sup>3</sup>, Mouriquand P.<sup>4</sup>, Morel-Journel N.<sup>3</sup>, Courtois F.<sup>5</sup>, Terrier J-E.<sup>3</sup>  
**Institutes:** <sup>1</sup>University Hospital of Saint-Etienne, Dept. of Urology, Saint-Etienne, France, <sup>2</sup>Henry Gabrielle Hospital, University Hospital of Lyon, Dept. of Neuro Perineal and Sexology Rehabilitation, Lyon, France, <sup>3</sup>South Lyon Hospital, University Hospital of Lyon, Dept. of Urology, Lyon, France, <sup>4</sup>Woman Mother Child Hospital, University Hospital of Lyon, Dept. of Urogenital Surgery, Visceral, Thoracic, Newborn and Transplantation, Lyon, France, <sup>5</sup>University of Québec, Dept. of Sexology, Montréal, Canada
- 888      **HIPEC with cytoreductive surgery can cure patients with limited peritoneal carcinomatosis from adenocarcinoma of the urachus**

**By:** [Behrendt M.A.](#)<sup>1</sup>, Mehta A.<sup>2</sup>, Boot H.<sup>3</sup>, Fransen Van De Putte E.<sup>1</sup>, Van Der Heijden M.<sup>4</sup>, Horenblas S.<sup>1</sup>, Moonen L.<sup>5</sup>, Verwaal V.<sup>6</sup>, Meinhardt W.<sup>1</sup>, Van Rhijn B.<sup>1</sup>

**Institutes:**<sup>1</sup>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, <sup>2</sup>Basingstoke and North Hampshire Hospital, Dept. of Colorectal Surgery, Hampshire, United Kingdom, <sup>3</sup>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Surgical Oncology, Amsterdam, The Netherlands, <sup>4</sup>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Oncology, Amsterdam, The Netherlands, <sup>5</sup>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Radiotherapy, Amsterdam, The Netherlands, <sup>6</sup>Catharina Ziekenhuis, Dept. of Surgical Oncology, Eindhoven, The Netherlands

889

**Encapsulating peritoneal sclerosis, a serious complication of peritoneal dialysis**

**By:** [Pourmand G.](#)<sup>1</sup>, Alatab S.<sup>1</sup>, Najafi I.<sup>2</sup>, Hosseini M.<sup>3</sup>, Ahmadbeigi N.<sup>4</sup>

**Institutes:**<sup>1</sup>Tehran University of Medical Sciences, Urology Research Center, Tehran, Iran, <sup>2</sup>Tehran University of Medical Sciences, Shariati Hospital, Nephrology Research Center, Tehran, Iran, <sup>3</sup>Tehran University of Medical Sciences, School of Public Health, Tehran, Iran, <sup>4</sup>Tehran University of Medical Sciences, Digestive Disease Research Institute, Liver and Pancreatobiliary Diseases Research Center, Tehran, Iran

890

**Female sexual function after intravesical therapy in patients with interstitial cystitis/bladder pain syndrome**

**By:** Arslan B.<sup>1</sup>, Cilesiz N.C.<sup>1</sup>, [Onuk O.](#)<sup>2</sup>, Cetin B.<sup>1</sup>, Yazıcı G.<sup>1</sup>, Hazar A.I.<sup>1</sup>, Aydin M.<sup>1</sup>

**Institutes:**<sup>1</sup>Gop Taksim Training and Research Hospital, Dept. of Urology, Istanbul, Turkey, <sup>2</sup>Yeniüyüzyil University, Dept. of Urology, Istanbul, Turkey

891

**Effect of Brimapitide on acute and chronic cystitis model induced by cyclophosphamide in conscious rats**

**By:** [Abadie C.](#)<sup>1</sup>, Chabot S.<sup>2</sup>, Augé C.<sup>2</sup>, Deloche C.<sup>1</sup>, Lluet P.<sup>2</sup>, Combette J-M.<sup>1</sup>

**Institutes:**<sup>1</sup>Solid Drug Development, Geneva, Switzerland, <sup>2</sup>UROsphere, Toulouse, France

892

**Withdrawn**

**By:**

**Institutes:**

893

**Time-dependent changes in urine markers in patients with interstitial cystitis**

**By:** [Furuta A.](#)<sup>1</sup>, Yamamoto T.<sup>2</sup>, Koike Y.<sup>1</sup>, Suzuki Y.<sup>3</sup>, Gotoh M.<sup>2</sup>, Egawa S.<sup>1</sup>, Yoshimura N.<sup>4</sup>

**Institutes:**<sup>1</sup>Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, <sup>2</sup>Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan, <sup>3</sup>Tokyo Metropolitan Rehabilitation Hospital, Dept. of Urology, Tokyo, Japan, <sup>4</sup>University of Pittsburgh School of Medicine, Dept. of Urology, Pittsburgh, United States of America

894

**The natural history of Leydig cell testicular tumours: An analysis of the National Cancer Registry in Ireland**

**By:** [Nason G.](#), Redmond E., Considine S., Izzeldin S., Sweeney P.

**Institutes:**Mercy University Hospital, Dept. of Urology, Cork, Ireland